Seres Therapeutics, Inc. (MCRB)

Seres Therapeutics, Inc. (MCRB) Healthcare & Pipeline Overview

Seres Therapeutics, Inc. pioneers microbiome therapeutics, developing bacterial consortia to treat diseases, with a focus on Clostridium difficile infection (CDI) and inflammatory bowel diseases. Their lead candidate, SER-109, represents a novel approach in the biotechnology sector, distinguishing them in a competitive landscape.

What Is the Investment Thesis for MCRB?

Seres Therapeutics presents a notable research candidate within the microbiome therapeutics space. The company's lead candidate, SER-109, has completed Phase III trials for Clostridium difficile infection (CDI), a significant milestone. Successful commercialization of SER-109 could drive substantial revenue growth. The company's pipeline, including SER-155, SER-287, and SER-301, targets other significant unmet medical needs, offering further growth potential. However, the company's negative profit margin of -4088.8% and gross margin of -20.9% indicate financial challenges. Upcoming clinical trial results for SER-155 and progress in the ulcerative colitis programs represent key catalysts. Potential risks include regulatory hurdles, competition, and the need for additional funding.

Based on FMP financials and quantitative analysis

MCRB Key Highlights

• SER-109 has completed Phase III clinical trials for the treatment of Clostridium difficile infection (CDI).
• SER-155 is in Phase Ib clinical trials to reduce infections in immunocompromised patients.
• The company has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center.
• Market capitalization of $74.66M.
• Profit margin of -4088.8% indicates significant losses.

Who Are MCRB's Competitors?

MCRB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MCRB's Key Strengths?

• Proprietary microbiome therapeutics platform.
• Lead product candidate (SER-109) has completed Phase III trials.
• Experienced management team.
• Collaborations with Nestec and Memorial Sloan Kettering.

What Are MCRB's Weaknesses?

• Negative profit margin.
• Limited revenue generation.
• Dependence on clinical trial success.
• Relatively small number of employees.

What Could Drive MCRB Stock Higher?

• Regulatory approval decision for SER-109 for Clostridium difficile infection (CDI).
• Clinical trial results for SER-155 in immunocompromised patients.
• Progress in the development of SER-287 and SER-301 for ulcerative colitis.
• Expansion of the microbiome therapeutics platform into new therapeutic areas.

What Are the Key Risks for MCRB?

• Financial-distress signal — its Altman Z-Score of -12.50 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory delays or rejection of SER-109.
• Clinical trial failures for pipeline candidates.
• Competition from other biotechnology companies.
• Need for additional funding to support research and development.
• Intellectual property challenges.

What Are the Growth Opportunities for MCRB?

• Commercialization of SER-109: The successful commercialization of SER-109 for Clostridium difficile infection (CDI) represents a significant growth opportunity for Seres. CDI affects hundreds of thousands of patients annually, with a high recurrence rate. SER-109's novel approach to restoring the gut microbiome could capture a substantial market share, generating significant revenue. The timeline for commercialization depends on regulatory approval, but potential launch could occur within the next 1-2 years.
• Development of SER-155: SER-155, currently in Phase Ib clinical trials, targets the reduction of infections in immunocompromised patients undergoing stem cell and organ transplantation. This represents a substantial market opportunity, as these patients are highly vulnerable to life-threatening infections. Positive clinical trial results and subsequent regulatory approval could lead to a valuable new product for Seres, expanding its therapeutic focus.
• Advancement of Ulcerative Colitis Programs: Seres is developing SER-287 and SER-301 for the treatment of ulcerative colitis, a chronic inflammatory bowel disease. The ulcerative colitis market is large and growing, with a significant unmet need for more effective and safer therapies. Positive clinical trial results for SER-287 and SER-301 could position Seres as a key player in this market.
• Expansion into New Therapeutic Areas: Seres has the potential to expand its microbiome therapeutics platform into new therapeutic areas beyond CDI, infections, and ulcerative colitis. The microbiome is implicated in a wide range of diseases, including metabolic disorders, autoimmune diseases, and cancer. By leveraging its expertise and technology, Seres could develop new therapies for these conditions, driving long-term growth.
• Partnerships and Collaborations: Seres can pursue strategic partnerships and collaborations to accelerate its research and development efforts and expand its market reach. The company already has collaborations with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Additional partnerships with pharmaceutical companies, academic institutions, and other organizations could provide access to new technologies, funding, and expertise.

What Opportunities Does MCRB Have?

• Commercialization of SER-109.
• Expansion into new therapeutic areas.
• Strategic partnerships and collaborations.
• Growing market for microbiome therapeutics.

What Threats Does MCRB Face?

• Regulatory hurdles.
• Competition from other biotechnology companies.
• Clinical trial failures.
• Need for additional funding.

What Are MCRB's Competitive Advantages?

• Proprietary microbiome therapeutics platform.
• Strong intellectual property portfolio.
• Clinical trial data demonstrating efficacy.
• Established collaborations with leading institutions.
• First-mover advantage in the microbiome therapeutics space.

What Does MCRB Do?

Seres Therapeutics, Inc., founded in 2010 and headquartered in Cambridge, Massachusetts, is a biotechnology company focused on developing microbiome therapeutics. The company's core technology involves creating bacterial consortia designed to interact with host cells and tissues to treat various diseases. Seres's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trials for the treatment of Clostridium difficile infection (CDI). This innovative approach aims to restore the gut microbiome's natural balance to combat CDI, a significant healthcare challenge. In addition to SER-109, Seres is developing SER-155, a cultivated bacteria microbiome drug currently in Phase Ib clinical trials. SER-155 targets the reduction of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation and solid organ transplants. The company's pipeline also includes SER-287 and SER-301, both in Phase Ib trials for ulcerative colitis, SER-401 for metastatic melanoma, and SER-262 for Clostridioides difficile infection. Seres Therapeutics collaborates with Nestec Ltd. and Memorial Sloan Kettering Cancer Center to advance its research and development efforts. Formerly known as Seres Health, Inc., the company changed its name in May 2015 to reflect its focus on microbiome therapeutics.

What Products and Services Does MCRB Offer?

• Develop microbiome therapeutics using bacterial consortia.
• Target diseases by functionally interacting with host cells and tissues.
• Develop oral microbiome therapeutics.
• Conduct clinical trials to evaluate the safety and efficacy of their products.
• Collaborate with other companies and institutions to advance research and development.
• Focus on Clostridium difficile infection (CDI) treatment.
• Develop therapies for ulcerative colitis and other inflammatory bowel diseases.

How Does MCRB Make Money?

• Develop and commercialize microbiome therapeutics.
• Generate revenue through product sales.
• Establish partnerships and collaborations for research and development funding.
• License technology to other companies.

What Industry Does MCRB Operate In?

Seres Therapeutics operates in the rapidly evolving biotechnology industry, specifically within the microbiome therapeutics segment. This area focuses on harnessing the power of the human microbiome to treat diseases. The market is characterized by increasing scientific understanding of the microbiome's role in health and disease, leading to new therapeutic approaches. Seres competes with other companies developing microbiome-based therapies, as well as traditional pharmaceutical companies. The industry is driven by the need for novel treatments for conditions like CDI and ulcerative colitis, where existing therapies have limitations. Success in this field requires strong scientific expertise, clinical trial execution, and regulatory navigation.

Who Are MCRB's Key Customers?

• Patients suffering from Clostridium difficile infection (CDI).
• Immunocompromised patients undergoing stem cell and organ transplantation.
• Patients with ulcerative colitis.
• Healthcare providers who prescribe and administer Seres's therapies.

FY2026 estForward Outlook

Wall Street analysts project Seres Therapeutics, Inc. revenue of about $12.9M for fiscal 2026, with EPS near $-7.51.

F-Score 2/9Financial Health

Seres Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.50 places it in the distress zone, a signal of elevated financial risk.

P/E 11.8Key Financial Metrics

Return on assets is -39.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -69.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -77.3%, the inverse of the P/E and a quick read on earnings relative to price.

Seres Therapeutics, Inc. (MCRB) Valuation Context

Valued at $74.66M, MCRB is classified as a micro-cap stock. Relative to its peer group, MCRB's quantitative score of 17/100 is below the peer average of 76/100.

Company Profile

Seres Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Richard N. Kender. MCRB has traded publicly since 2015.

MCRB Financials

MCRB Latest News

MCRB Analyst Consensus

MCRB MoonshotScore

Common Questions About MCRB (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources